Blood News and Research

RSS

High CRP and low protein albumin levels associated with increased risk of death after PEG-operations

The combination of high CRP and low levels of the protein albumin in the blood, is associated with an increased risk of death after a PEG-operation; implantation of a nutritional catheter into the stomach through the abdominal wall. This was shown in a new study from the Swedish medical university Karolinska Institutet, published in the scientific journal Gastrointestinal Endoscopy. Of the PEG patients in the study that showed both current indicators, 20 percent died within 30 days.

20 Nov 2010

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

20 Nov 2010

USC Norris designated Phase I Clinical Trial Center of Excellence

The USC Norris Comprehensive Cancer Center (USC Norris) has been designated a Phase I Clinical Trial Center of Excellence by global pharmaceutical company Bristol-Myers Squibb Company. The collaboration will bring a number of new phase I clinical trials to USC Norris, and will enable the cancer center's clinical and basic scientists to provide guidance in early phase drug development and trial design.

20 Nov 2010

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

The first American study that positions Platelet Rich Plasma Therapy (PRP) as a viable means in managing knee osteoarthritis, appeared today in the December issue of the American Journal of Physical Medicine & Rehabilitation (AJPMR). The study, authored by Dr. Steven Sampson of the Orthohealing Center in Los Angeles, details the account of 14 patients with primary and secondary knee osteoarthritis receiving three platelet-rich plasma injections in the affected knee at 4-week intervals with one year follow up.

20 Nov 2010

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

State roundup: California PPOs 'low marks'; Geriatric nursing; Physician shortages

News outlets covered a range of developments including workforce issues in Minnesota and California, and a Kentucky order for insurers to provide child-only policies.

19 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

From Baxter International Inc. 19 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

MedStart Summer Enrichment Program helps students better understand medical conditions: Studies

Two new studies have shown that a unique program in East Harlem that helps middle school students learn practical health skills and gain a better understanding of medical conditions, such as diabetes and hypertension, resulted in increased interest in college attendance and medical careers among the students who attended the program.

19 Nov 2010

ENERCA network organizes European Symposium on rare anemias

It is estimated that rare diseases -those whose frequency is under 5 cases / 10,000 people- affect about 6% of the European population. In the field of anemia, 1% of couples are at risk of having a newborn with a severe syndrome of hemoglobin. More than 330,000 children are born worldwide each year affected by one of these diseases, being the most common disorders sickle cell anemia and thalassemia syndromes.

19 Nov 2010

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston.

19 Nov 2010

Acacia subsidiary receives patents for wireless physiological monitoring technology

Acacia Research Corporation announced today that a subsidiary has acquired 11 patents for wireless physiological monitoring technology.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Research suggests new therapeutic approach to prevent transplant rejection

UCLA researchers have pinpointed the culprit behind chronic rejection of heart, lung and kidney transplants. Published in the Nov. 23 edition of Science Signaling, their findings suggest new therapeutic approaches for preventing transplant rejection and sabotaging cancer growth.

19 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

African Americans have faster rates of decline in kidney function

African Americans along with some groups of Hispanics have faster rates of decline in kidney function compared to white Americans, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

19 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Blood News and Research

High CRP and low protein albumin levels associated with increased risk of death after PEG-operations

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

USC Norris designated Phase I Clinical Trial Center of Excellence

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

State roundup: California PPOs 'low marks'; Geriatric nursing; Physician shortages

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

MedStart Summer Enrichment Program helps students better understand medical conditions: Studies

ENERCA network organizes European Symposium on rare anemias

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Acacia subsidiary receives patents for wireless physiological monitoring technology

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Research suggests new therapeutic approach to prevent transplant rejection

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

ACE-041 drug may provide new option to treat cancer

African Americans have faster rates of decline in kidney function

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News